FR2556219B1 - Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines - Google Patents

Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines

Info

Publication number
FR2556219B1
FR2556219B1 FR8319568A FR8319568A FR2556219B1 FR 2556219 B1 FR2556219 B1 FR 2556219B1 FR 8319568 A FR8319568 A FR 8319568A FR 8319568 A FR8319568 A FR 8319568A FR 2556219 B1 FR2556219 B1 FR 2556219B1
Authority
FR
France
Prior art keywords
fragments
human igg
subfragments
properties
igg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR8319568A
Other languages
English (en)
French (fr)
Other versions
FR2556219A1 (fr
Inventor
Edgardo D Carosella
Jacques Armand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Merieux SA
Original Assignee
Institut Merieux SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR8319568A priority Critical patent/FR2556219B1/fr
Application filed by Institut Merieux SA filed Critical Institut Merieux SA
Priority to US06/679,445 priority patent/US4719107A/en
Priority to DE19843444765 priority patent/DE3444765A1/de
Priority to DE198484402531T priority patent/DE147283T1/de
Priority to JP59259048A priority patent/JPS60185726A/ja
Priority to DE8484402531T priority patent/DE3479398D1/de
Priority to AT84402531T priority patent/ATE45498T1/de
Priority to CA000469658A priority patent/CA1229791A/fr
Priority to EP84402531A priority patent/EP0147283B1/fr
Publication of FR2556219A1 publication Critical patent/FR2556219A1/fr
Application granted granted Critical
Publication of FR2556219B1 publication Critical patent/FR2556219B1/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
FR8319568A 1983-12-07 1983-12-07 Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines Expired FR2556219B1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
FR8319568A FR2556219B1 (fr) 1983-12-07 1983-12-07 Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines
DE19843444765 DE3444765A1 (de) 1983-12-07 1984-12-07 Immunmodulierendes arzneimittel
DE198484402531T DE147283T1 (de) 1983-12-07 1984-12-07 Immunmodulierendes arzneimittel basiert auf fe fragmenten menschlichen iggs.
JP59259048A JPS60185726A (ja) 1983-12-07 1984-12-07 免疫調整医薬
US06/679,445 US4719107A (en) 1983-12-07 1984-12-07 Immunomodulating medication based on Fc fragments of human IgG
DE8484402531T DE3479398D1 (en) 1983-12-07 1984-12-07 Immunomodulating medicine based on fc fragments of human igg
AT84402531T ATE45498T1 (de) 1983-12-07 1984-12-07 Immunmodulierendes arzneimittel basiert auf fc fragmenten menschlichen ig gs.
CA000469658A CA1229791A (fr) 1983-12-07 1984-12-07 Composition medicamenteuse a base de fragments fc d'igg humaines
EP84402531A EP0147283B1 (fr) 1983-12-07 1984-12-07 Nouveau médicament immunomodulateur, à base de fragments Fc d'IgG Humaines

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8319568A FR2556219B1 (fr) 1983-12-07 1983-12-07 Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines

Publications (2)

Publication Number Publication Date
FR2556219A1 FR2556219A1 (fr) 1985-06-14
FR2556219B1 true FR2556219B1 (fr) 1987-06-26

Family

ID=9294941

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8319568A Expired FR2556219B1 (fr) 1983-12-07 1983-12-07 Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines

Country Status (7)

Country Link
US (1) US4719107A (https=)
EP (1) EP0147283B1 (https=)
JP (1) JPS60185726A (https=)
AT (1) ATE45498T1 (https=)
CA (1) CA1229791A (https=)
DE (3) DE3444765A1 (https=)
FR (1) FR2556219B1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62153300A (ja) * 1985-12-26 1987-07-08 Teijin Ltd ヒト免疫グロブリンＧＦｃ領域蛋白質およびその製造方法
US4925920A (en) * 1987-05-29 1990-05-15 Brigham And Women's Hospital Immunosuppressive polypeptides
US4814433A (en) * 1987-09-16 1989-03-21 Miles Inc. Method for obtaining a papain-free antibody fragment preparation
GB8824869D0 (en) * 1988-10-24 1988-11-30 Stevenson G T Synthetic antibody
US5681566A (en) * 1988-10-24 1997-10-28 3I Research Exploitation Limited Antibody conjugates with two or more covalently linked FC regions
FR2639231A1 (fr) * 1988-11-23 1990-05-25 Merieux Inst Utilisation de fragments fc d'immunoglobulines g humaines, de peptides analogues du fragment fc, ou d'immunoglobulines g humaines dans l'obtention d'un medicament preparatoire a l'administration chez l'homme, dans un but therapeutique ou de diagnostic, d'anticorps monoclonaux
US5328834A (en) * 1989-09-08 1994-07-12 Unisyn Technologies, Inc. Method for preparing immunoglobulin fragments
GB9009106D0 (en) * 1990-04-23 1990-06-20 3I Res Expl Ltd Processes and intermediates for synthetic antibody derivatives
US5230887A (en) * 1990-07-11 1993-07-27 Immune Network Research Ltd. Immune system stabilizers for prevention and therapy of disorders associated with immune system disfunction
US5219578A (en) * 1991-02-25 1993-06-15 Innovet, Inc. Composition and method for immunostimulation in mammals
US7211258B2 (en) * 2002-04-10 2007-05-01 Protalex, Inc. Protein A compositions and methods of use
US7425331B2 (en) * 2002-04-10 2008-09-16 Protalex, Inc. Protein A methods of use
US8460665B2 (en) * 2003-05-16 2013-06-11 Mayo Foundation For Medical Education And Research Compositions and methods including a recombinant human MAB that promotes CNS remyelination
ATE501173T1 (de) * 2003-12-04 2011-03-15 Abbott Biotherapeutics Corp Anti-ip-10-antikörper
US20080206246A1 (en) * 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US8470318B2 (en) * 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US20080286819A1 (en) * 2005-11-07 2008-11-20 Ravetch Jeffrey V Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof
MX2008012843A (es) * 2006-04-05 2009-01-19 Univ Rockefeller Polipeptidos con propiedades antiinflamatorias aumentadas y citotoxicas reducidas y metodos relacionados.
AU2008211227B2 (en) 2007-01-30 2014-04-17 Epivax, Inc. Regulatory T cell epitopes, compositions and uses thereof
US20110150867A1 (en) * 2007-12-14 2011-06-23 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
WO2009132130A2 (en) * 2008-04-22 2009-10-29 The Rockefeller University Methods of identifying anti-inflammatory compounds
JP2017518965A (ja) 2014-05-02 2017-07-13 モメンタ ファーマシューティカルズ インコーポレイテッ エンジニアリングされたＦｃ構築物に関連する組成物および方法
WO2017151971A2 (en) 2016-03-02 2017-09-08 Momenta Pharmaceuticals, Inc. METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
BR112018074056A2 (pt) 2016-05-23 2019-03-06 Momenta Pharmaceuticals, Inc. composições e métodos relacionados a construtos de fc manipulados
CN110650748B (zh) 2017-01-06 2024-01-02 动量制药公司 与经工程改造的Fc构建体相关的组合物和方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2222083B1 (https=) * 1973-03-22 1976-05-14 Fontaine Michel
FR2267115B1 (https=) * 1974-04-12 1977-11-10 Merieux Inst
DE2846412A1 (de) * 1978-10-25 1980-05-08 Behringwerke Ag Mittel zur behandlung allergischer reaktionen
DE2853453A1 (de) * 1978-12-11 1980-06-19 Behringwerke Ag Mittel zur therapie von immunkomplexerkrankungen
JPS5821623A (ja) * 1981-07-28 1983-02-08 Tetsuzo Sugizaki 抗原抗体複合体沈着疾患治療剤
JPS5821624A (ja) * 1982-04-06 1983-02-08 Tetsuzo Sugizaki 慢性関節リウマチの治療剤
DE3364347D1 (en) * 1982-04-09 1986-08-07 Fujirebio Kk Anti immune complex antibody and preparation thereof
US4465670A (en) * 1982-07-23 1984-08-14 Dainippon Pharmaceutical Co., Ltd. Method for the treatment of systemic lupus erythematosus and primary glomerulonephritis and agent therefor

Also Published As

Publication number Publication date
DE3444765A1 (de) 1985-06-20
EP0147283A3 (en) 1985-08-14
ATE45498T1 (de) 1989-09-15
EP0147283B1 (fr) 1989-08-16
CA1229791A (fr) 1987-12-01
JPS60185726A (ja) 1985-09-21
FR2556219A1 (fr) 1985-06-14
DE3479398D1 (en) 1989-09-21
EP0147283A2 (fr) 1985-07-03
US4719107A (en) 1988-01-12
DE147283T1 (de) 1986-04-10
JPH0586378B2 (https=) 1993-12-10

Similar Documents

Publication Publication Date Title
FR2556219B1 (fr) Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines
DE68916932D1 (de) Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus.
EP0552256A4 (https=)
AU3322089A (en) Anti-t-cell receptor determinants as autoimmune disease treatment
IT8223795A0 (it) Gamma), relativi veicoli di polipeptidi contenenti la sequenza espressione, loro procedimento di degli amminoacidi dell'interferone preparazione, composizioni umano immune (interferone umano farmaceutiche contenenti tali polipeptidi.
RU95106651A (ru) Аналоги дзе-тур динорфина и способ лечения толерантных состояний у пациента
PT76831B (en) Process for preparing teichomycin a2 pure single factors 1,2,3,4 and 5 and of pharmaceutical compositions containing the same
SE9002589L (sv) Neutrofil-aktiverande peptid-2
IL72985A0 (en) Homogenous immune interferon fragment,its manufacture and pharmaceutical compositions containing it
ES2052507T3 (es) Peptido, proceso para su sintesis, compuesto farmaceutico que lo contiene y utilizacion del mismo.
MY102918A (en) Purified antineoplaston fractions and methods of treating neoplastic disease.
KR880011198A (ko) 사이클릭 펩타이드 및 이의 제조방법
IL103065A0 (en) Protein for inhibiting platelet aggregation,processes for the preparation thereof and a pharmaceutical composition containing the same
CA1187869A (en) Deca- undeca- dodeca and tridecapeptides with thymic activity
CA1281288C (en) Tumor therapy
GB9311454D0 (en) Pharmaceutical compositions
Waxman et al. The presence of specific antigen-reactive cells during the induction, recovery, and resistance phases of experimental allergic encephalomyelitis
ATE183652T1 (de) Synthetische peptide für die behandlung von myasthenia gravis
Wleklik et al. Tuftsin, a natural peptide with antiviral activity-structural basis of its action
GB1590457A (en) Thymosin a1
AU1464488A (en) Human rhinovirus peptides
IT8748235A0 (it) Peptidi e derivati peptidici, loro preparazione e loro impiego come medicamenti
Hoessli et al. Variations in the structure of surface glycoproteins present in different lymphocyte subpopulations
DE3162674D1 (en) A purified polypeptide, a process for its preparation, its use and pharmaceutical compositions containing it
KR870010080A (ko) 면역촉진 활성을 갖는 트리펩티드

Legal Events

Date Code Title Description
ST Notification of lapse